Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab for pruritus in adults with lichen simplex chronicus
jRCT2031240549Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in neurodermatitis comparing Dupilumab with Placebo (2 arms). Primary endpoint: Proportion of participants with at least 4-point reduction in weekly average daily WI-NRS at Week 24. Started Dec 2024; status: active, not recruiting.
02
Drugs
03
Conditions
neurodermatitis
Beyond the preview
Go deeper on jRCT2031240549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240549.